Literature DB >> 18022643

Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression.

Yo-Tsen Liu1, Yi-Chung Lee, Chih-Chao Yang, Mai-Ling Chen, Kon-Ping Lin.   

Abstract

BACKGROUND: Transthyretin (TTR) variants of familial amyloid neuropathies (FAP) form a heterogenous group of autosomal dominantly inherited diseases. TTR gene analysis in several nationalities (Japanese, Portuguese, French, and British) has shown many distinguishing characteristics in the genotype-phenotype correlation. In Chinese, there are only a few reports of private TTR gene mutations belonging to single kindred.
MATERIALS AND METHODS: We collected five patients with autosomal dominant inheritant sensorimotor polyneuropathy and tissue-proved amyloid deposition. The diagnosis of FAP was established on the mutation of the TTR gene detected by direct sequencing. Haplotype analysis was conducted in four of these patients. RESULTS AND
CONCLUSIONS: These five FAP patients shared an identical missense mutation, Ala97Ser, in the TTR gene. This mutation presented with a constellation of late-onset polyneuropathy, preceding carpal tunnel syndrome, and outstanding autonomic dysfunction. Heart was the most frequently involved vital organ. Haplotype analysis hinted independent origins although the numbers were limited. Our study is the first case series gathering from the Chinese-Taiwanese population. We proposed a possible hot-spot mutation of the TTR gene, Ala97Ser, in this ethnic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022643     DOI: 10.1016/j.jns.2007.10.011

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Multimodal retinal imaging in a Chinese kindred with familial amyloid polyneuropathy secondary to transthyretin Ile107Met mutation.

Authors:  W Lv; J Chen; W Chen; P Hou; C P Pang; H Chen
Journal:  Eye (Lond)       Date:  2014-01-31       Impact factor: 3.775

2.  Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China.

Authors:  Shuai Wang; Wenke Peng; Min Pang; Ling Mao; Daoquan Peng; Bilian Yu; Sha Wu; Die Hu; Yang Yang; Jia He; Mingqi Ouyang
Journal:  Front Cardiovasc Med       Date:  2022-06-27

3.  A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy.

Authors:  Qian Chen; Lamei Yuan; Xiong Deng; Zhijian Yang; Shengwang Zhang; Sheng Deng; Hongwei Lu; Hao Deng
Journal:  Mol Neurobiol       Date:  2017-07-31       Impact factor: 5.590

4.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

5.  Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan.

Authors:  Hua-Chuan Chao; Yi-Chu Liao; Yo-Tsen Liu; Yuh-Cherng Guo; Fu-Pang Chang; Yi-Chung Lee; Kon-Ping Lin
Journal:  Ann Clin Transl Neurol       Date:  2019-04-09       Impact factor: 4.511

6.  Hereditary Transthyretin Amyloidosis in Eight Chinese Families.

Authors:  Ling-Chao Meng; He Lyu; Wei Zhang; Jing Liu; Zhao-Xia Wang; Yun Yuan
Journal:  Chin Med J (Engl)       Date:  2015-11-05       Impact factor: 2.628

7.  Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese.

Authors:  Hui-Ching Hsu; Ming-Feng Liao; Jung-Lung Hsu; Ai-Lun Lo; Hung-Chou Kuo; Rong-Kuo Lyu; Victor Chien-Chia Wu; Chih-Wei Wang; Long-Sun Ro
Journal:  BMC Neurol       Date:  2017-09-07       Impact factor: 2.474

8.  Biophysical characterization and modulation of Transthyretin Ala97Ser.

Authors:  Yo-Tsen Liu; Yueh-Jung Yen; Frans Ricardo; Yu Chang; Pei-Hao Wu; Shing-Jong Huang; Kon-Ping Lin; Tsyr-Yan Yu
Journal:  Ann Clin Transl Neurol       Date:  2019-09-10       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.